TW200736262A - Heteroalkyl linked pyrimidine derivatives - Google Patents

Heteroalkyl linked pyrimidine derivatives

Info

Publication number
TW200736262A
TW200736262A TW095142288A TW95142288A TW200736262A TW 200736262 A TW200736262 A TW 200736262A TW 095142288 A TW095142288 A TW 095142288A TW 95142288 A TW95142288 A TW 95142288A TW 200736262 A TW200736262 A TW 200736262A
Authority
TW
Taiwan
Prior art keywords
compounds
pyrimidine derivatives
heteroalkyl
linked pyrimidine
heteroalkyl linked
Prior art date
Application number
TW095142288A
Other languages
English (en)
Other versions
TWI407961B (zh
Inventor
Stephanie Blanchard
Kantharaj Ethirajulu
Cheng-Hsia Angeline Lee
Harish Kumar Mysore Nagaraj
Anders Poulsen
Eric T Sun
Yee Ling Evelyn Tan
Ee Ling Teo
Anthony Deodaunia William
Original Assignee
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltd filed Critical S Bio Pte Ltd
Publication of TW200736262A publication Critical patent/TW200736262A/zh
Application granted granted Critical
Publication of TWI407961B publication Critical patent/TWI407961B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW95142288A 2005-11-16 2006-11-15 雜烷基連接之嘧啶衍生物 TWI407961B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73683805P 2005-11-16 2005-11-16
US81733906P 2006-06-30 2006-06-30
US85128306P 2006-10-13 2006-10-13

Publications (2)

Publication Number Publication Date
TW200736262A true TW200736262A (en) 2007-10-01
TWI407961B TWI407961B (zh) 2013-09-11

Family

ID=38048928

Family Applications (3)

Application Number Title Priority Date Filing Date
TW103101503A TWI525096B (zh) 2005-11-16 2006-11-15 氧連接之嘧啶衍生物
TW095142296A TWI506029B (zh) 2005-11-16 2006-11-15 氧連接之嘧啶衍生物
TW95142288A TWI407961B (zh) 2005-11-16 2006-11-15 雜烷基連接之嘧啶衍生物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW103101503A TWI525096B (zh) 2005-11-16 2006-11-15 氧連接之嘧啶衍生物
TW095142296A TWI506029B (zh) 2005-11-16 2006-11-15 氧連接之嘧啶衍生物

Country Status (20)

Country Link
US (5) US8153632B2 (zh)
EP (1) EP1951729B1 (zh)
JP (2) JP5225856B2 (zh)
KR (5) KR101513492B1 (zh)
CN (2) CN101360751B (zh)
AT (1) ATE469158T1 (zh)
AU (2) AU2006316072B2 (zh)
BR (1) BRPI0618552B8 (zh)
CA (2) CA2629443C (zh)
CY (1) CY1116156T1 (zh)
DE (1) DE602006014579D1 (zh)
DK (2) DK1951729T3 (zh)
ES (2) ES2346791T3 (zh)
HK (2) HK1123282A1 (zh)
MY (1) MY148072A (zh)
NZ (1) NZ568325A (zh)
PL (1) PL1951729T3 (zh)
PT (2) PT1951729E (zh)
TW (3) TWI525096B (zh)
WO (2) WO2007058627A1 (zh)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697384B1 (en) 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US10517876B2 (en) * 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
EP2044084B1 (en) 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
BRPI0808524A2 (pt) 2007-03-01 2014-11-11 Chugai Pharmaceutical Co Ltd Composto macrocíclico
WO2008140420A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyrimidine derivatives
WO2008140419A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyridyl substituted pyrimidine derivatives
BRPI0814542A2 (pt) * 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
US8318929B2 (en) 2008-03-10 2012-11-27 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
MX2011006206A (es) * 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.
DK2376500T3 (en) * 2008-12-11 2015-05-04 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt
BR112012000750B1 (pt) 2009-07-15 2021-05-25 Cti Biopharma Corp. sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo
EP2531197B1 (en) * 2010-02-05 2017-05-17 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
CN102757448B (zh) * 2011-04-26 2016-04-06 中南大学 大环类激酶抑制剂化合物、制备方法及其作为药物的应用
ES2583477T3 (es) * 2011-09-30 2016-09-21 Ipsen Pharma S.A.S. Inhibidores macrocíclicos de cinasa de LRRK2
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN102617599B (zh) * 2012-04-10 2014-04-16 江苏先声药物研究有限公司 大环类化合物及其应用
EP2970213A4 (en) * 2013-03-14 2016-09-07 Concert Pharmaceuticals Inc PACRITINIB DEUTÉRIÉ
CA2911259A1 (en) * 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
MA39823A (fr) * 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
FR3025200B1 (fr) * 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
FR3025199B1 (fr) * 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
EA032838B1 (ru) 2014-09-17 2019-07-31 Онкодизайн С.А. Макроциклические ингибиторы lrrk2-киназы
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
WO2016149031A1 (en) * 2015-03-18 2016-09-22 Newave Pharmaceutical Llc Covalent inhibitors of cdk-7
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法
CN105017282B (zh) * 2015-08-28 2017-11-07 苏州明锐医药科技有限公司 帕克替尼的制备方法
US20180318306A1 (en) * 2015-09-28 2018-11-08 Cti Biopharma Corp. Methods of treating transplant rejection
JP6888000B2 (ja) * 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
EP3432888B1 (en) * 2016-03-24 2022-10-05 Cothera Bioscience, Inc. Treatment of cancer with tg02
WO2017196261A1 (en) * 2016-05-11 2017-11-16 National University Of Singapore Jak and hdac dual-inhibitor compounds
IL272697B2 (en) * 2017-08-18 2023-12-01 Adastra Pharmaceuticals Inc A polymorphic form of TG02
WO2019079357A1 (en) * 2017-10-17 2019-04-25 Silverback Therapeutics, Inc. TNIK MODULATORS, CONJUGATES AND USES THEREOF
CN108864145B (zh) * 2018-09-14 2021-03-30 兆科（广州）肿瘤药物有限公司 一种氧联嘧啶衍生物的纯化方法
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
KR20210105375A (ko) * 2018-12-19 2021-08-26 키테라 (쑤저우) 파마슈티컬스 컴퍼니 리미티드 Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020219606A1 (en) 2019-04-22 2020-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of erk5 inhibitors for treating gliomas in pediatric subjects
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN113583020B (zh) * 2020-04-30 2022-04-22 百极弘烨（广东）医药科技有限公司 一种jak2抑制剂及应用
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨（广东）医药科技有限公司 一种大环jak抑制剂及其应用
WO2022056092A1 (en) * 2020-09-11 2022-03-17 Cti Biopharma Corp. Methods of treating viral infection
CN115490705A (zh) * 2021-06-18 2022-12-20 成都凡诺西生物医药科技有限公司 N-大环酰胺类化合物、其制备方法及其作为药物的应用
CN113603708B (zh) * 2021-07-27 2023-08-11 中国药科大学 一种具有大环骨架结构的cdk9抑制剂的制备及其应用
CN114409674B (zh) * 2022-01-28 2023-07-25 山东大学 一种JAK抑制剂Pacritinib的合成方法
CN117964628A (zh) * 2022-10-24 2024-05-03 科辉智药生物科技(深圳)有限公司 作为cdk9抑制剂的大环类化合物及其应用
CN117447407A (zh) * 2023-12-19 2024-01-26 潍坊医学院 一种JAK2抑制剂Pacritinib及其中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
DE69819501T2 (de) 1997-06-27 2004-09-23 Ciba Speciality Chemicals Holding Inc. Ruthenium und osmiumcarbenkatalysatoren
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
AU2003275681B8 (en) * 2002-10-29 2009-03-26 Msd K.K. Novel quinoxalinone derivatives
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050096324A1 (en) * 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
SG151288A1 (en) * 2003-12-18 2009-04-30 Janssen Pharmaceutica Nv 3-cyano-quinoline derivatives with antiproliferative activity
EP1697384B1 (en) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US9047780B2 (en) * 2012-11-16 2015-06-02 Robert Bosch Gmbh Collision mitigation systems and methods using driver attentiveness

Also Published As

Publication number Publication date
CA2629443A1 (en) 2007-05-24
MY148072A (en) 2013-02-28
BRPI0618552A2 (pt) 2011-09-06
TWI407961B (zh) 2013-09-11
PL1951729T3 (pl) 2015-02-27
CN101360751B (zh) 2011-09-14
PT1951729E (pt) 2014-10-02
WO2007058627A1 (en) 2007-05-24
KR20140037256A (ko) 2014-03-26
EP1951729A4 (en) 2009-09-23
JP2009515954A (ja) 2009-04-16
CN101360751A (zh) 2009-02-04
US20090258886A1 (en) 2009-10-15
TWI506029B (zh) 2015-11-01
KR101576159B1 (ko) 2015-12-09
KR20140037257A (ko) 2014-03-26
AU2006316071A1 (en) 2007-05-24
PT1951730E (pt) 2010-08-27
EP1951729A1 (en) 2008-08-06
KR101513492B1 (ko) 2015-04-20
KR20080090390A (ko) 2008-10-08
US9573964B2 (en) 2017-02-21
US20120142680A1 (en) 2012-06-07
WO2007058628A1 (en) 2007-05-24
JP2009517344A (ja) 2009-04-30
JP5225856B2 (ja) 2013-07-03
KR101568801B1 (ko) 2015-11-12
KR20140117679A (ko) 2014-10-07
TW200738735A (en) 2007-10-16
HK1123282A1 (zh) 2009-06-12
US8153632B2 (en) 2012-04-10
BRPI0618552B1 (pt) 2021-04-06
ATE469158T1 (de) 2010-06-15
HK1124040A1 (en) 2009-07-03
DK1951730T3 (da) 2010-09-27
CA2629455C (en) 2017-01-03
BRPI0618552B8 (pt) 2021-05-25
CN101365703A (zh) 2009-02-11
EP1951729B1 (en) 2014-06-25
AU2006316072A1 (en) 2007-05-24
TWI525096B (zh) 2016-03-11
US20120196855A1 (en) 2012-08-02
DK1951729T3 (da) 2014-10-06
CA2629443C (en) 2016-12-13
CA2629455A1 (en) 2007-05-24
US8415338B2 (en) 2013-04-09
DE602006014579D1 (de) 2010-07-08
US20130172338A1 (en) 2013-07-04
JP5380073B2 (ja) 2014-01-08
CN101365703B (zh) 2013-11-06
AU2006316072B2 (en) 2011-12-22
NZ568325A (en) 2011-05-27
US9133214B2 (en) 2015-09-15
ES2346791T3 (es) 2010-10-20
AU2006316071B2 (en) 2011-02-17
ES2506040T3 (es) 2014-10-13
US8143255B2 (en) 2012-03-27
CY1116156T1 (el) 2017-02-08
KR101499594B1 (ko) 2015-03-09
TW201418263A (zh) 2014-05-16
KR20080086443A (ko) 2008-09-25
US20090075999A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
TW200736262A (en) Heteroalkyl linked pyrimidine derivatives
HK1145832A1 (en) Pyrimidine substituted purine derivatives
TW200639173A (en) Substituted pyrazolopyridines, compositions containing same, manufacturing process therefor and use thereof
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2009010047A (es) Compuestos quimicos.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009010045A (es) Compuestos quimicos.
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
MY148948A (en) Catecholamine derivatives and prodrugs thereof
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
TW200734334A (en) Treatment of substance abuse
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
EP1812112A4 (en) CHEMICAL COMPOUNDS
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
NZ594186A (en) Indole derivatives as anticancer agents
TW200640858A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
WO2008140420A3 (en) Pyrimidine derivatives
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie
WO2008140419A3 (en) Pyridyl substituted pyrimidine derivatives
WO2008140421A3 (en) Heterocycloalkyl substituted pyrimidine derivatives